Welcome to our dedicated page for Bioatla news (Ticker: BCAB), a resource for investors and traders seeking the latest updates and insights on Bioatla stock.
BioAtla, Inc. (Nasdaq: BCAB) is a global clinical-stage biotechnology company developing Conditionally Active Biologic (CAB) antibody therapeutics for solid tumors, and its news flow reflects the progress of this platform. Company announcements regularly describe updates on CAB-based antibody-drug conjugates and bispecific T-cell engagers, regulatory interactions, financing arrangements, and strategic collaborations.
Recent BioAtla news has highlighted the clinical and regulatory path for ozuriftamab vedotin (Oz-V), a CAB-Platform ROR2-targeting ADC. Releases describe compelling Phase 2 data in HPV-positive oropharyngeal squamous cell carcinoma (OPSCC), FDA Fast Track Designation for certain squamous cell carcinoma of the head and neck patients, and FDA alignment on a randomized Phase 3 trial design with dual primary endpoints. Additional coverage explains a special purpose vehicle (SPV) transaction with Inversagen AI, LLC and GATC Health Corp. intended to fund a registrational Oz-V trial in OPSCC while BioAtla retains a majority ownership interest in the Oz-V asset.
News items also focus on mecbotamab vedotin (Mec-V), a CAB AXL-targeting ADC in Phase 2 development, including clinical data in treatment-refractory soft tissue sarcomas and mKRAS non-small cell lung cancer. For BA3182, a CAB EpCAM x CAB CD3 bispecific T-cell engager, BioAtla has reported preliminary Phase 1 results in metastatic adenocarcinoma patients, describing a manageable safety profile and prolonged tumor control at higher dose levels.
Investors following BCAB news will also see regular updates on financial results, cash runway, and capital structure. The company has announced Pre-Paid Advance Agreements and a Standby Equity Purchase Agreement that provide flexible equity-linked financing, as well as a special meeting of stockholders to consider approval of potential share issuances and a possible reverse stock split. Additional releases discuss Nasdaq listing compliance milestones, patent coverage, and licensing agreements such as the worldwide license to Context Therapeutics for a CAB Nectin-4 x CD3 T-cell engager.
For those tracking oncology pipelines, regulatory milestones, and financing developments in clinical-stage biotech, the BioAtla news page offers ongoing detail on how the CAB platform and its lead programs are progressing. Investors and observers can use this stream of press releases to monitor trial design decisions, data presentations at major medical congresses, partnership activity and key corporate events related to BCAB stock.
BioAtla (NASDAQ:BCAB) reported Q2 2025 financial results and clinical progress updates. The company's Phase 1 CAB-EpCAM x CAB-CD3 bispecific T-cell engager (BA3182) showed promising results with seven patients achieving tumor size reductions ranging from -5% to -25%. Their Fast Track Designated ozuriftamab vedotin (Oz-V) demonstrated strong efficacy in HPV+ head and neck cancer with a 45% overall response rate and 100% disease control rate.
Financial results showed R&D expenses decreased to $13.7M from $16.2M year-over-year, while net loss improved to $18.7M from $21.1M. The company ended Q2 with $18.2M in cash, down from $49.0M at 2024 year-end, and expects decreased quarterly cash burn as Phase 2 trials conclude. BioAtla remains confident in closing at least one partnership transaction in 2025.
BioAtla (Nasdaq: BCAB), a clinical-stage biotechnology company specializing in Conditionally Active Biologic (CAB) antibody therapeutics for solid tumor treatment, has scheduled its Q2 2025 earnings conference call for August 7, 2025, at 4:30 p.m. ET.
The company will discuss financial results for the quarter ended June 30, 2025, and provide business updates. The earnings release will be available on the company's website before the call. Investors can access the call through the provided domestic and international dial-in numbers or via webcast.
BioAtla (Nasdaq: BCAB), a clinical-stage biotechnology company, will present at the 2025 ESMO TAT Asia Meeting in Hong Kong from July 18-20, 2025. The company will deliver an oral presentation about their first-in-human phase I study of BA3182, a dual-Conditionally Active Biologic (CAB) EpCAM x CD3 bispecific T-cell engager for treating refractory metastatic adenocarcinoma.
The presentation will be given by Jennifer B. Brooke Valerin on July 18, 2025 at 15:59-16:06 GMT+8. The presentation materials will be available on BioAtla's website after the event.
BioAtla (NASDAQ:BCAB) presented promising first-in-human data for BA3182, their dual-conditionally binding EpCAM x CD3 bispecific T-cell engager, at the 2025 ESMO Gastrointestinal Cancers Congress. The ongoing Phase 1 trial included 39 heavily pretreated patients with metastatic adenocarcinoma, receiving doses ranging from 0.0026 mg to 0.6 mg weekly.
Key findings showed five patients achieved objective tumor size reductions ranging from -8% to -25%, with two colorectal carcinoma patients showing prolonged progression-free intervals of 11 and 14 months. Adverse events were generally low-grade and manageable, with subcutaneous dosing showing an improved plasma profile compared to intravenous administration. The trial continues dose escalation at 1.2 mg weekly, with updated Phase 1 data expected in 2H2025.
BioAtla (Nasdaq: BCAB), a global clinical-stage biotechnology company, has announced its upcoming participation in the Citizens Life Sciences Conference in New York. The company, which specializes in developing Conditionally Active Biologic (CAB) antibody therapeutics for solid tumor treatment, will deliver a corporate update and engage in one-on-one investor meetings.
The presentation is scheduled for Wednesday, May 7, 2025, at 10:00 a.m. ET in New York. Company management will be available for individual investor discussions during the two-day conference, which runs from May 7-8, 2025. A webcast link has been provided for those interested in following the corporate update remotely.
BioAtla, a global clinical-stage biotechnology company, has scheduled its first quarter 2025 financial results announcement and business highlights conference call for May 6, 2025, at 4:30 p.m. ET.
The company, which specializes in developing Conditionally Active Biologic (CAB) antibody therapeutics for solid tumor treatment, will host both a conference call and webcast. Investors and interested parties can access the event through:
- Domestic dial-in: (800) 245-3047
- International dial-in: (203) 518-9765
- Conference ID: BIOATLA
Financial results will be available before the conference call via the "News Releases" section on BioAtla's website. A replay of the presentation will be accessible through the "Events & Presentations" section in the Investors area of the company website.
BioAtla (BCAB) has announced two poster presentations at the upcoming 2025 American Association for Cancer Research (AACR) Annual Meeting in Chicago from April 25-30, 2025. The presentations will showcase the company's proprietary Conditionally Active Biologic (CAB) technology.
The first poster demonstrates CAB anti-Nectin4-antibody drug conjugate's superior efficacy compared to enfortumab vedotin analogue in multiple cancer models. The second presentation focuses on novel senolytic targets and CAB-based drug conjugates for targeting senescence-associated secretory phenotype cells.
The presentations will be held on April 27 and April 28, 2025, featuring research by authors including Jian Chen, Jing Wang, and others. The CAB technology aims to provide a new generation of biologics with improved safety margins and therapeutic index, specifically targeting acidic senescence in cancer and age-related diseases.
BioAtla (BCAB), a clinical-stage biotech company specializing in Conditionally Active Biologic (CAB) antibody therapeutics for solid tumors, has announced an upcoming poster presentation at the 2025 ASCO Annual Meeting. The event will be held both online and at Chicago's McCormick Place Convention Center from May 30–June 3, 2025.
The presentation will feature Phase 2 trial results of ozuriftamab vedotin (BA3021), a conditionally binding ROR2-ADC, in treating patients with heavily pretreated squamous cell carcinoma of the head and neck. The poster presentation (Abstract #6048, Poster #456) is scheduled for Monday, June 2, 2025, from 9:00 AM to 12:00 PM CDT during the Head and Neck Cancer session.